Results from Incyte's (INCY) Oral 11beta-HSD1 Inhibitor, INCB13739, Study Presented at ADA
Tweet Send to a Friend
Incyte Corporation (Nasdaq: INCY) announced over the weekend clinical results of its Phase IIb trial of INCB13739, an orally bioavailable ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
